AstraZeneca's MedImmune Gets Creative In Diabetes With PCSK9/GLP-1 Fusion Product
Executive Summary
AstraZeneca PLC's MedImmune LLC will be the first drug developer to present data for a "fusion molecule" therapy combining a PCSK9 antibody with a GLP-1 peptide when a Phase I trial of its pioneering product MEDI-4166 in type 2 diabetics completes later this year. The company's head of diabetes innovative medicines, Cristina Rondinone, explains to Scrip the thought process behind the unique combination and what to expect for further development of the novel drug in 2017.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.